Edition:
United Kingdom

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

5.79USD
18 Apr 2019
Change (% chg)

$-0.10 (-1.70%)
Prev Close
$5.89
Open
$5.86
Day's High
$5.96
Day's Low
$5.72
Volume
54,870
Avg. Vol
44,182
52-wk High
$67.10
52-wk Low
$5.20

Latest Key Developments (Source: Significant Developments)

First Light Asset Management Reports 13.45 Pct Passive Stake In Endologix Inc As Of April 3
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Endologix Inc ::FIRST LIGHT ASSET MANAGEMENT LLC REPORTS 13.45 PERCENT PASSIVE STAKE IN ENDOLOGIX INC AS OF APRIL 3 - SEC FILING.  Full Article

Endologix Sees Q1 2019 Revenue About $35 Million
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.26.SEES Q1 2019 REVENUE ABOUT $35 MILLION.Q4 REVENUE $34.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $32 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.20 -- REFINITIV IBES DATA.REAFFIRMS ITS PREVIOUSLY ISSUED ANNUAL GUIDANCE.FY2019 EARNINGS PER SHARE VIEW $-0.52, REVENUE VIEW $141.6 MILLION -- REFINITIV IBES DATA.Q1 REVENUE VIEW $32.7 MILLION -- REFINITIV IBES DATA.  Full Article

Endologix Sees Q1 Revenue About $35 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 PRELIMINARY FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL GUIDANCE.SEES Q1 2019 REVENUE ABOUT $35 MILLION.SEES FY 2018 REVENUE $155.8 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.SEES Q4 2018 REVENUE ABOUT $34 MILLION.TOTAL CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AS OF DECEMBER 31, 2018 ARE EXPECTED TO BE APPROXIMATELY $24 MILLION.ANTICIPATES REVENUE FOR Q1 ENDING MARCH 31, 2019 OF APPROXIMATELY $35 MILLION.CONTINUES TO EXPECT 2019 OPERATING EXPENSES IN RANGE OF $130 MILLION TO $140 MILLION.ENDOLOGIX - 2019 FINANCIAL GUIDANCE CONTEMPLATES ANTICIPATED IMPACT OF VOLUNTARY RECALL OF NELLIX SYSTEM, ISSUANCE OF JAN 4, 2019 FIELD SAFETY NOTICE.CONTINUES TO EXPECT 2019 REVENUE OF AT LEAST $140 MILLION.Q4 REVENUE VIEW $31.1 MILLION -- REFINITIV IBES DATA.Q1 REVENUE VIEW $31.9 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $140.8 MILLION -- REFINITIV IBES DATA.  Full Article

Endologix Reports Q3 Revenue $34.8 Million
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.SEES FY 2018 GAAP LOSS PER SHARE $0.87 TO $0.91.Q3 LOSS PER SHARE $0.12.Q3 REVENUE $34.8 MILLION VERSUS I/B/E/S VIEW $34.5 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.CONTINUES TO ANTICIPATE 2018 REVENUE IN RANGE OF $150 MILLION TO $155 MILLION.2019 OPERATING EXPENSES ANTICIPATED TO BE IN RANGE OF $130 MILLION TO $140 MILLION.FY2019 REVENUE VIEW $142.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $151.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $-0.79 -- THOMSON REUTERS I/B/E/S.  Full Article

Endologix Announces Public Offering Of Common Stock
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.ENDOLOGIX INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $20.0 MILLION OF ITS SHARES OF COMMON STOCK.ENDOLOGIX - INTENDS TO USE NET PROCEEDS FROM OFFERING TO REDEEM ALL $18.3 MILLION 2.25% CONVERTIBLE SENIOR NOTES DUE 2018.  Full Article

FDA Classifies Previous Endologix Afx Safety Notice As Class I Recall
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Endologix Inc ::FDA CLASSIFIES PREVIOUS ENDOLOGIX AFX SAFETY NOTICE AS CLASS I RECALL.ENDOLOGIX- RECEIVED NOTICE THAT FDA CLASSIFIED VOLUNTARY RECALL ACTION THAT CO TOOK IN JULY OF THIS YEAR AS A CLASS I RECALL.ENDOLOGIX INC - JULY RECALL INVOLVED CO'S ISSUANCE OF A SAFETY NOTICE TO HEALTHCARE PROFESSIONALS USING AFX ENDOVASCULAR AAA SYSTEM.ENDOLOGIX - NO PRODUCT WAS REMOVED FROM FIELD AS PART OF JULY RECALL.  Full Article

Endologix Announces Q3 Revenue Results, Raises Low-End Of FY Revenue Guidance
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES THIRD QUARTER PRELIMINARY REVENUE RESULTS AND RAISES LOW END OF 2018 REVENUE GUIDANCE RANGE.SEES Q3 2018 REVENUE $34.3 MILLION TO $34.7 MILLION.NOW ANTICIPATES 2018 REVENUE TO BE IN RANGE OF $150 MILLION TO $155 MILLION.  Full Article

Japan Lifeline says termination of joint research and development contract on Thoracic Stent Grafts
Friday, 28 Sep 2018 

Sept 28(Reuters) - Japan Lifeline Co Ltd <7575.T>:Says it has reached agreement with Endologix Inc <<>> to terminate the joint development contract related to thoracic stent graft system as of October 1.The joint product development agreement related to thoracic stent graft system was signed by the parties in September 2017.In conjunction with the termination of the contract related to development of a thoracic stent graft system, the two companies have also agreed to terminate the exclusive sales agreement for Japan concerning the thoracic stent graft system.  Full Article

Endologix Reports Q2 Loss Per Share Of $0.28
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.SEES FY 2018 GAAP LOSS PER SHARE $1.04 TO $1.12.Q2 LOSS PER SHARE $0.28.SEES FY 2018 REVENUE $145 MILLION TO $155 MILLION.Q2 REVENUE $44.7 MILLION VERSUS I/B/E/S VIEW $44.4 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.TOTAL CASH, CASH EQUIVALENTS, AND RESTRICTED CASH WERE $37.6 MILLION AS OF JUNE 30, 2018.FY2018 EARNINGS PER SHARE VIEW $-0.58, REVENUE VIEW $175.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Endologix Inc Files For Mixed Shelf Of Upto $100 Million
Thursday, 31 May 2018 

May 31 (Reuters) - Endologix Inc ::ENDOLOGIX INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article